FIRMAGON 80 mg powder and solvent for solution for injection

DRUG5 trials

Sponsors

Turku University Central Hospital, Ziekenhuis Aan De Stroom, UZ Leuven

Conditions

Intermediate-risk prostate cancerOligorecurrent hormone-sensitive prostate cancer patientsProstate cancerbenign prostate hyperplasiaprostate cancer

Phase 1

Effect of neoadjuvant Degarelix on MRI-guided transurethral ultrasound ablation in patients with intermediate-risk prostate cancer: A pilot study

Active, not recruitingCTIS2022-502067-38-00

Turku University Central HospitalIntermediate-risk prostate cancer

Start: 2023-06-29Target: 15Updated: 2023-05-12

Phase 2

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

RecruitingCTIS2022-501551-90-00

Ziekenhuis Aan De StroomProstate cancer

Start: 2023-12-13Target: 583Updated: 2026-01-23

A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy

Not yet recruitingCTIS2024-512023-37-00

Ziekenhuis Aan De StroomProstate cancer

Target: 202Updated: 2025-09-11

Phase 3

Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.

RecruitingCTIS2022-502373-42-00

UZ LeuvenOligorecurrent hormone-sensitive prostate cancer patients

Start: 2022-04-25Target: 873Updated: 2025-03-31

Phase 4

Prostate medication, metabolism and gut microbiota, PROMED.

RecruitingCTIS2022-500618-24-00

Turku University Central Hospitalbenign prostate hyperplasia, prostate cancer

Start: 2022-12-01Target: 100Updated: 2022-10-04